Armed with positive Phase IIa data in Type I diabetes, Tolerion Inc. is now seeking funding for a second go at developing a selective immunomodulatory approach that previously failed in multiple sclerosis.

In 2011, Tolerion plucked TOL-3021 from the ashes of defunct autoimmune disease company Bayhill Therapeutics Inc., which wound down after BHT-3009 failed in a Phase IIb trial to treat MS.